Berlin, May 16, 2018 – Medios AG (‘Medios’), one of the leading Specialty Pharma companies in Germany, has enjoyed a successful start to the 2018 financial year and confirms the forecast for the full year after a significant increase in sales and earnings in the first quarter. In the period from January to March, Group sales rose by 32 per cent to 68.6 million euros (IFRS; prior year EUR 51.8 million) compared to the same quarter last year. Without taking into account the 2017 stock option program (SOP) and one-off expenses of approximately 0.3 million euros within the context of the proposed acquisition and integration of the operating units of BerlinApotheke Schneider & Oleski oHG, Group earnings before taxes (EBT) climbed by 20 per cent to 2.4 million euros (IFRS; prior year EUR 2.0 million). After one-off expenses, the EBT increased by 5 per cent to 2.1 million euros without taking the SOP into account.
Manfred Schneider, CEO of Medios AG: ‘With the positive business development in the first quarter and continuing high demand for individualised medicine, we remain optimistic about achieving our targets for the full year and continuing the dynamic growth path as planned.’
The Management Board is confirming its forecast, which assumes that the acquired operating units will be integrated and make a significant contribution to Group sales and EBT from June 2018. For the 2018 financial year, the Management Board therefore continues to expect Group sales of around 320 million euros and an EBT, without taking into account the SOP, of approximately 11 million euros. This represents a considerable growth of 26 per cent and 37 per cent respectively compared to 2017 financial figures totalling 253 million euros and 8.0 million euros respectively.
About Medios AG
Medios AG is one of the leading Specialty Pharma companies in Germany. As wholesaler for Specialty Pharma drugs and GMP-certified manufacturer of patient-specific medications, Medios covers substantial elements of the supply chain in this field and follows the highest international quality standards. Specialty Pharma drugs are, in particular, individualised infusions for patients with rare or chronic diseases like cancer, HIV and hepatitis. It is Medios’ aim to provide integrated solutions along the value chain to partners and clients, thereby ensuring an optimal pharmaceutical care for patients.
Medios AG is Germany’s first listed Specialty Pharma company. The share (WKN: A1MMCC, ISIN: DE000A1MMCC8) is listed in the Regulated Market of the Frankfurt Stock Exchange (General Standard) and Hamburg-Hannover Stock Exchange.
Kirchhoff Consult AG
Telephone: +49 40 60918618
Fax: +49 40 60918660
This notification contains forward-looking statements that are subject to certain risks and uncertainties. Future results may significantly deviate from currently expected results, specifically due to various risk factors and uncertainties such as changes in business, economic, and competitive circumstances, exchange rate fluctuations, uncertainties about legal disputes or investigations, and the availability of financial resources. Medios AG assumes no responsibility whatsoever for updating the forward-looking statements contained in this notification.